🇺🇸 Rituxan +CHOP in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 6
Most-reported reactions
- Catheter Site Discharge — 1 report (16.67%)
- Catheter Site Erythema — 1 report (16.67%)
- Febrile Neutropenia — 1 report (16.67%)
- Hypotension — 1 report (16.67%)
- Nausea — 1 report (16.67%)
- Vomiting — 1 report (16.67%)
Other Oncology approved in United States
Frequently asked questions
Is Rituxan +CHOP approved in United States?
Rituxan +CHOP does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rituxan +CHOP in United States?
Shandong New Time Pharmaceutical Co., LTD is the originator. The local marketing authorisation holder may differ — check the official source linked above.